Neumora Therapeutics, Inc. 8-K

What Happened
Neumora Therapeutics, Inc. announced on January 12, 2026 (via Form 8-K), that it has made a corporate presentation available for use in meetings with investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference. The disclosure was made under Item 7.01 (Regulation FD Disclosure) and the presentation is furnished as Exhibit 99.1 to the filing.

Key Details

• Date of filing: January 12, 2026 (Form 8-K).
• Event: 44th Annual J.P. Morgan Healthcare Conference (investor and analyst meetings).
• Exhibit: Corporate presentation dated January 2026 is furnished as Exhibit 99.1.
• Regulatory note: Disclosure reported under Item 7.01 (Regulation FD); exhibits listed under Item 9.01 include Exhibit 99.1 and the Inline XBRL cover page (Exhibit 104).

Why It Matters
This 8-K makes Neumora’s investor presentation publicly available, so shareholders and potential investors can review the company’s latest corporate messaging presented at a major industry conference. The filing is a formal, broad disclosure (Regulation FD) rather than a report of financial results or corporate changes—no earnings, executive appointments, mergers, or financial metrics were announced in this filing.